/

Empresas

Sh

No verificado

Shionogi USA

Sobre qué escribimos

CienciaFarmacéuticaIndustriaMedicina - VariosSalud

9 Comunicados de prensa

Ver todos los comunicados de prensa

20/10/2025

Salud

Ciencia

Sanidad

Farmacéutica

Biotecnología

Eventos

IDWeek 2025: Shionogi Presents Real-World and Surveillance Data Reinforcing Role of Cefiderocol Across Range of Patient Populations and Difficult-to-Treat Infections

Fuente

Editor

1.00

0

03/09/2025

Ciencia

Medicina - Varios

Biotecnología

Salud

Farmacéutica

Sanidad

Eventos

Ferias y Congresos

Industria

Shionogi to Present New Data from Anti-Infective Portfolio at IDWeek

Fuente

Editor

1.00

0

02/09/2025

Farmacéutica

Sanidad

Salud

Higiene alimentaria

Medicina - Varios

Industria

FDA Accepts Shionogi’s Ensitrelvir NDA as the First Oral Therapy for the Prevention of COVID-19 Following Exposure

Fuente

Editor

1.00

0

12/03/2025

Industria

Ciencia

VIH, SIDA y enfermedades autoinmunes

Medicina - Varios

Sanidad

Biotecnología

Farmacéutica

Salud

Late-Breaking at CROI 2025: SCORPIO-PEP Phase 3 Trial: Ensitrelvir is the First and Only COVID-19 Oral Antiviral to Demonstrate Prevention of COVID-19 as Post Exposure Prophylaxis

Fuente

Editor

1.00

0

04/02/2025

Ciencia

Farmacéutica

Sanidad

Salud

Higiene alimentaria

Medicina - Varios

Mercado laboral

Industria

Shionogi and Jordan’s Guardian Angels Announce First-Ever Human Drug Study for Jordan’s Syndrome, an Ultra-Rare Genetic Neurodevelopmental Disorder

Fuente

Editor

1.00

0

16/01/2025

Eventos

Mercado laboral

Industria

Ciencia

Sanidad

Salud

VIH, SIDA y enfermedades autoinmunes

Medicina - Varios

Shionogi Receives Award Through BARDA's Rapid Response Partnership Vehicle to Advance Long-Acting Formulation of S-892216, an Antiviral for COVID-19 Pre-Exposure Prophylaxis in At-Risk Populations

Fuente

Editor

1.00

0

16/10/2024

Eventos

Industria

Salud

VIH, SIDA y enfermedades autoinmunes

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

IDWeek 2024: Shionogi Presents Largest Global Real-World Evidence Study of Cefiderocol Demonstrating Strong Clinical Response Rates Across Seriously Ill Patients

Fuente

Editor

1.00

0

04/09/2024

Oncología

Salud

VIH, SIDA y enfermedades autoinmunes

Medicina - Varios

Farmacéutica

Biotecnología

Eventos

Industria

Shionogi Continues Global Commitment to Advances in Infectious Disease with Key Data Presentations from Its Expanding Product Portfolio at IDWeek 2024

Fuente

Editor

1.00

0

18/07/2024

Ciencia

Sanidad

Familia

Farmacéutica

Ir de compras

Biotecnología

Medicina - Varios

Higiene alimentaria

Salud

Eventos

Industria

Shionogi Provides Updates on Zatolmilast, an Investigational Drug for Fragile X Syndrome, Including Recent Changes to Study Protocol to Increase Access for Participants and Families

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0